Free Trial
LON:HLN

Haleon (HLN) Share Price, News & Analysis

Haleon logo
GBX 398.10 -0.20 (-0.05%)
As of 06:25 AM Eastern

About Haleon Stock (LON:HLN)

Key Stats

Today's Range
396.80
399.20
50-Day Range
357.60
416.56
52-Week Range
319.84
419.50
Volume
74.92 million shs
Average Volume
26.87 million shs
Market Capitalization
£35.93 billion
P/E Ratio
33.48
Dividend Yield
1.51%
Price Target
GBX 457
Consensus Rating
Buy

Company Overview

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

Haleon Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

HLN MarketRank™: 

Haleon scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Haleon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Haleon has received no research coverage in the past 90 days.

  • Read more about Haleon's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Haleon is 33.52, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.51.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Haleon is 33.52, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.11.

  • Price to Earnings Growth Ratio

    Haleon has a PEG Ratio of 1.49. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Haleon has a P/B Ratio of 2.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for HLN.
  • Dividend Yield

    Haleon has a dividend yield of 0.02%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Haleon does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Haleon is 50.46%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about Haleon's dividend.
  • Short Interest

    There is no current short interest data available for HLN.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Haleon this week, compared to 1 article on an average week.
  • Search Interest

    5 people have searched for HLN on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Haleon insiders have bought more of their company's stock than they have sold. Specifically, they have bought £172,941.04 in company stock and sold GBX 0 in company stock.

  • Percentage Held by Insiders

    10.74% of the stock of Haleon is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    43.88% of the stock of Haleon is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Haleon's insider trading history.
Receive HLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haleon and its competitors with MarketBeat's FREE daily newsletter.

HLN Stock News Headlines

Haleon plc (LON:HLN) Insider Buys £86,265 in Stock
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

HLN Stock Analysis - Frequently Asked Questions

Haleon's stock was trading at GBX 377.40 at the beginning of the year. Since then, HLN stock has increased by 5.6% and is now trading at GBX 398.54.
View the best growth stocks for 2025 here
.

Haleon plc (LON:HLN) announced its earnings results on Friday, February, 28th. The company reported $15.80 earnings per share (EPS) for the quarter. Haleon had a net margin of 9.66% and a trailing twelve-month return on equity of 6.54%.

Shares of HLN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Haleon investors own include GSK (GSK), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Cisco Systems (CSCO), Meta Platforms (META) and Unilever (ULVR).

Company Calendar

Last Earnings
2/28/2025
Record date for 6/5 Dividend
4/24/2025
Ex-Dividend for 6/5 Dividend
4/24/2025
Dividend Payable
6/05/2025
Today
6/11/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Consumer Goods
Current Symbol
LON:HLN
CIK
N/A
Fax
N/A
Employees
25,408
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 457
High Stock Price Target
GBX 457
Low Stock Price Target
GBX 457
Potential Upside/Downside
+14.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
33.60
Forward P/E Ratio
20.48
P/E Growth
1.49
Net Income
£1.07 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£11.07 billion
Cash Flow
GBX 18.20 per share
Price / Cash Flow
21.95
Book Value
GBX 182.02 per share
Price / Book
2.19

Miscellaneous

Outstanding Shares
9,025,597,051
Free Float
N/A
Market Cap
£36.06 billion
Optionable
Not Optionable
Beta
0.19
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (LON:HLN) was last updated on 6/12/2025 by MarketBeat.com Staff
From Our Partners